CymaBay Therapeutics (CBAY) Tops Q2 EPS by 33c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street slides as AI cash burn worries spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil prices set for fourth straight monthly gains as tanker attack highlights supply risks
Tweet
Share
E-mailGet Alerts CBAY Hot Sheet
Join SI Premium – FREE
CymaBay Therapeutics (NASDAQ: CBAY) reported Q2 EPS of ($0.09), $0.33 better than the analyst estimate of ($0.42).
For earnings history and earnings-related data on CymaBay Therapeutics (CBAY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stifel on FedEx Freight (FDXF): 'Enters Its Post-Breakup Era - Time to Hit the Gym and Focus on Itself'
- Standard Motor Products (SMP) Tops Q3 EPS by 4c
- SanDisk stock tumbles as Kioxia warns on NAND price surge
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
